|
Video: What is a Stock Split?
|
|
Opthea is a biopharmaceutical company. Co. develops and commercializes therapies mainly for eye disease. Co.'s primary asset, OPT-302, is a soluble form of Vascular Endothelial Growth Factors (VEGF) Receptor-3 in clinical development as a therapy for wet (neovascular) age-related macular degeneration (Wet AMD) and diabetic macular edema (DME). Wet AMD and DME are the main causes of blindness in the elderly and diabetic populations respectively. Co.'s development activities are based on an intellectual property portfolio covering primary targets (VEGF-C, VEGF-D and VEGF Receptor-3) for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. According to our Opthea stock split history records, Opthea has had 0 splits. | |
|
Opthea (OPT) has 0 splits in our Opthea stock split history database.
Looking at the Opthea stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Opthea shares, starting with a $10,000 purchase of OPT, presented on a split-history-adjusted basis factoring in the complete Opthea stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
10/19/2020 |
|
End date: |
04/26/2024 |
|
Start price/share: |
$13.15 |
|
End price/share: |
$3.40 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-74.14% |
|
Average Annual Total Return: |
-31.90% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$2,585.75 |
|
Years: |
3.52 |
|
|
|
|
|